This brand name is authorized in Australia, Austria, Canada, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, UK, United States.
The drug FOSRENOL contains one active pharmaceutical ingredient (API):
1
|
UNII
490D9F069T - LANTHANUM CARBONATE
|
|
Lanthanum is indicated as a phosphate binding agent for use in the control of hyperphosphataemia. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| FOSRENOL Oral powder | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| FOSRENOL Chewable tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| V03AE03 | Lanthanum carbonate | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 5780F, 5781G, 5782H, 9403X, 9404Y, 9405B, 9635D, 9636E, 9637F |
| CA | Health Products and Food Branch | 02287145, 02287153, 02287161, 02287188 |
| EE | Ravimiamet | 1234864, 1234875, 1234886, 1234897, 1234910, 1234932, 1234943, 1234954, 1234965, 1235001, 1235012, 1235023, 1235034, 1235045, 1235056, 1235078, 1235089, 1235090, 1235102, 1235113, 1235124, 1517172, 1517183 |
| ES | Centro de información online de medicamentos de la AEMPS | 68434, 68438, 68439, 76053, 76054 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 023066, 023080, 023088, 043582, 162294 |
| FR | Base de données publique des médicaments | 62429857, 63357492, 63909453, 65651521, 67840531 |
| GB | Medicines & Healthcare Products Regulatory Agency | 112724, 112727, 112730, 209118, 209121 |
| HK | Department of Health Drug Office | 55610 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 6489, 6490, 6491, 7954 |
| JP | 医薬品医療機器総合機構 | 2190029D1025, 2190029D2021, 2190029F1026, 2190029F2022, 2190029F3029, 2190029F4025 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1022543, 1022544, 1022545, 1026500, 1026503, 1026504, 1026507, 1026510, 1026512, 1026514 |
| NL | Z-Index G-Standaard, PRK | 102504, 102512, 80128, 80136, 86843 |
| NZ | Medicines and Medical Devices Safety Authority | 20146, 20147, 20148, 20149, 20150 |
| PL | Rejestru Produktów Leczniczych | 100160249, 100160261, 100160278, 100295400, 100295423 |
| SG | Health Sciences Authority | 13594P, 13595P, 13596P |
| US | FDA, National Drug Code | 54092-252, 54092-253, 54092-254, 54092-256, 54092-257 |
| ZA | Health Products Regulatory Authority | 41/18/0299, 41/18/0300, 41/18/0301, 41/18/0302 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.